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ABSTRACT 
 
A common problem in the development of biopharmaceutical proteins is the lack of 
understanding around the implications of aggregation, or of their gradual, often partial 
degradation. Often aggregated or degraded protein variants comprise a small percentage of 
a biopharmaceutical protein sample, so it is difficult to assess their true impact on product 
quality and clinical efficacy. The assumption that biopharmaceutical producers adopt is 
that partially degraded or aggregated protein variants are necessarily undesirable, which 
may not always be the case. This problem is relevant to the enzyme L-asparaginase from 
the plant pathogen Erwinia chrysanthemi (ErA, or Erwinase), which is used as a treatment 
for acute lymphoblastic leukaemia (ALL). This research programme has addressed this 
issue by examining the effect of potentially adverse changes in ErA relative to its in vitro 
kinetic properties, and ultimately, to its in vivo pharmaceutical efficacy. Two factors 
potentially impacting ErA, deamidation and aggregation, were studied in detail. With 
respect to deamidation, an improvement on published methods for its detection in ErA was 
developed using a combination of capillary isoelectric focussing (cIEF) and strong 
chemical denaturants, and this novel method should be widely applicable to other proteins. 
Deamidation of ErA at selected, theoretically labile residues (N41 and N281, classed as 
labile using the sequence motif), through expression, purification and characterisation of 
engineered deamidated mutants, was found to improve, not hinder, the catalytic 
performance of the enzyme. The structural and kinetic changes imparted by deamidation 
at these sites were also found to closely mimic an enzyme with high identity and 
homology (L-asparaginase from Erwinia carotovora). Deamidation of ErA was shown to 
be at least partially induced during the cell lysis stage of manufacturing, and strategies for 
minimising creation of deamidated degradants were proposed. ErA aggregation was also 
studied by examining the aggregate profile in the insoluble, sub-visible 2 - 10µm range. 
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Protein particulates in this size range had been previously postulated as playing a role in 
immune-mediated allergic reactions during clinical administration of protein 
biopharmaceuticals such as L-asparaginases. Statistical analyses of allergic response 
during clinical use of ErA were compared to the lot-to-lot quantification of sub-visible 
protein particles. The results indicated that ErA allergic response was essentially 
independent of the level of sub-visible particulates. In summary, the outputs of this 
research have shown that ErA deamidation and aggregation products are not necessarily 
deleterious to enzymatic function and clinical efficacy. The work has also demonstrated a 
set of empirical strategies that may be employed more widely in the development of 
biopharmaceutical products. 
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1.1 BACKGROUND 
 
1.2 Introduction 
 
Proteins are complex molecules which are ubiquitous in nature and perform functions in 
almost all biological processes. They are constructed from one or more linear chains of 
covalently-linked amino acids. The polypeptide chains typically assume a three- 
dimensional shape after translation, in a process known as folding (Cooper, 2000). Under 
most circumstances, a correctly-folded protein should adopt a native conformation to 
perform its function, as is the case for proteinaceous enzymes, proteins which facilitate a 
chemical reaction. It is important to note that not only proteins can act as enzymes; for 
instance, ribozymes are ribonucleic acid (RNA) molecules that can catalyse certain 
biochemical reactions in a manner analogous to proteinaceous enzymes (Doudna and 
Cech, 2002). 
There are many proteins and enzymes that are manufactured at a large scale and used in a 
variety of ways. A protein from a given organism or cell line can be produced by 
culturing at a suitable scale using fermenters, isolation from the host cell, and purification 
using techniques such as affinity chromatography. Modern biotechnology techniques, 
such as recombinant DNA technology, have made the production of proteins and enzymes 
a routine endeavour in both industry and research environments. Enzymes may be 
employed as industrial biocatalysts to perform complex organic reactions with 
stereoselectivity, and in many cases they are specifically designed for enhanced activity 
using techniques such as directed evolution (Dalby, 2011; Hibbert and Dalby 2005). 
Another significant use for proteins and enzymes produced at industrial scale is as 
biopharmaceutical products for the medical treatment of disease in humans. Although 
important from a medical and ethical point of view, the production of biopharmaceutical 
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products is increasingly significant in economic terms. The world-wide biopharmaceutical 
market was estimated at USD 140 billion in 2012, with annual growth projected year-on- 
year as approximately 15 – 18% (Langer, 2012). 
Proteins that are used as biopharmaceutical products must undergo rigorous  analysis 
before use in humans, and this activity is strictly controlled by governmental oversight. 
New biopharmaceutical products are intensely studied for their in vivo efficacy and safety 
during pre-clinical (animal models) and clinical (human) studies. After successful passage 
through these stages, the potential product is approved by governmental regulatory bodies 
(in the UK, the Medicines and Healthcare Products Regulatory Agency or MHRA) and 
subsequently may be produced for release to the market. Each batch of the protein or 
enzyme that is produced must be analysed using a wide variety of techniques, to assure 
that the quality of the product is consistent and fit for medicinal use. Some of the factors 
which should be analysed include quantification of the proportion of protein material 
which is degraded or altered, as these factors may impact the efficacy of the protein as a 
drug (e.g., increased immune reactivity or decreased enzymatic activity). 
Pharmaceutical manufacture and storage may result in chemical and physical changes to 
the protein such as deamidation, aggregation and oxidation. In particular, deamidation and 
oxidation may be classed as post-translational modifications (PTM), which occur not only 
during in vitro handling (as for biopharmaceuticals) but also during many biological 
processes in vivo and after long-term storage. Protein aggregation is another process that 
can occur during pharmaceutical manufacture and may result in reduced biological 
activity. For biopharmaceuticals, the results of these changes (aggregation and 
deamidation) are classed as degraded protein variants, the presence of which may affect 
the stability, efficacy and/or clinical impact of the product. Often, proteins used as 
biopharmaceuticals may contain a small proportion of such degraded variants at the time 
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of clinical administration. Due to the influence of regulatory bodies during 
biopharmaceutical development, it is usually assumed that these degraded variants are 
undesirable or deleterious to clinical use, which may not always be the case. Thus, a 
common problem in the development of biopharmaceutical proteins is a lack of 
understanding around the implications of product degradation. 
This problem is particularly relevant to the enzyme L-asparaginase from the plant 
pathogen Erwinia chrysanthemi (ErA, or Erwinase®), which is used as a treatment for 
acute lymphoblastic leukaemia (ALL). Therefore, the aim of the research programme 
described here is to relate the effect of degradative changes in ErA to its in vitro kinetic 
properties, and ultimately, to its in vivo pharmaceutical efficacy. Two of the most common 
undesirable changes (deamidation and aggregation) to ErA have been studied during the 
course of this research. The relevant literature for L-asparaginase deamidation and 
aggregation is summarised in the sections below. 
 
 
 
 
 
1.3 Protein Degradation by Deamidation 
 
The term deamidation refers to the removal of an amide group from an organic compound 
via a chemical reaction. In the context of proteins and peptides, deamidation refers to a 
loss of an amide group from the side-chain residue of either asparagine (N or Asn) or 
glutamine (Q or Gln). Deamidation reactions may be mediated by enzymatic means or 
may occur due to non-enzymatic reactions (Aswad, 1995). Deamidation reactions that 
occur naturally in vivo have been hypothesised to serve as intra-cellular regulators, or 
‘molecular clocks’, for the overall control of the timing of biological processes (Robinson 
and Robinson, 2004). 
15  
Non-enzymatic deamidation is one of the most frequent degradation reactions to occur in 
proteins and peptides (Yang and Zubarev, 2010) and is much more common in Asn 
residues compared with Gln residues. In a deamidation reaction involving an Asn residue 
(Figure 1), the α-nitrogen C-terminal to the Asn attacks the side-chain carboxylate group, 
resulting in a succinimide intermediate and the release of ammonia. The cyclic 
succinimide intermediate is then spontaneously hydrolysed to form a mixture of Asp and 
isoAsp (Aswad et al., 2000). Completion of the reaction leads to a lowering of the protein 
pI due to the change in residue charge from neutral to negative. This degradation reaction 
causes charge heterogeneity in protein products and the creation of acidic protein variants. 
Deamidation is a common degradation reaction in proteins and peptides, and may occur 
even at physiological pH. However, an alkaline environment or an increase in temperature 
may increase the propensity of Asn residues to undergo deamidation. The neighbouring 
residues in the protein primary structure also play a role in determining whether a given 
Asn residue will undergo deamidation. The amino acid residue C-terminal to Asn has 
been shown to be critical in determining the rate of deamidation, with glycine (sequence of 
Xxx-Asn-Gly-Xxx) resulting in the highest rates of deamidation, up to 70-fold more than 
other residues (Tyler-Cross and Schirch, 1991; Patel and Borchardt, 1990). 
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In the context of biopharmaceutical proteins, deamidation is undesirable, but perhaps to a 
certain extent unavoidable. Deamidation may lead to loss of secondary, tertiary and/or 
quaternary structure thus compromising protein function and/or enzyme activity (Gupta 
and Srivastava, 2004; Dutta et al., 2012). However, the impact of a particular deamidation 
event is difficult to characterise fully. Understanding the impact of deamidation (and 
charge-variants in general) usually involves isolation by preparative HPLC and may be 
extremely laborious (Zhang et al., 2011; Khawli et al., 2010). The isolated species may 
have multiple post-translational modifications, making it difficult to address the impact of 
an individual modification on protein or enzyme function. Finally, the HPLC-isolated 
charge variants may have a different stability profile, further complicating their 
characterisation. 
An alternative strategy to study and characterise the impact of protein deamidation is by 
production of recombinant deamidated variants. Production of a recombinant deamidated 
form of a protein by heterologous expression and subsequent purification offers an 
alternative route to study the variant in isolation and understand its true biochemical, 
biophysical and functional properties. Recombinant deamidated variants have not been 
previously described in the literature in the context of understanding biopharmaceutical 
degradation and the impact on efficacy. However, multiple researchers have studied 
recombinant deamidated forms of lens crystallin proteins αA (Gupta and  Srivastava 
2004a; Chaves et al., 2008), αB (Gupta and Srivastava 2004b; Mafia et al., 2008), and 
βB1 and others (Lampi et al., 2001; Takata et al., 2008) in the context of understanding 
the impact of deamidation on human cataract formation. Also, outside of a 
biopharmaceutical context, deamidation at certain amino acid residue positions was shown 
to have an impact on enzyme activity using recombinant variants of a serine 
hydroxymethyltransferase (di Salvo et al., 1999). 
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As an established biopharmaceutical product, L-asparaginase is a good model for studying 
the effect of deamidation, as the activity of the enzyme depends on maintaining its 
quaternary structure. Thus, in addition to deamidation near the active site residues, 
deamidation at a site that changes the propensity of the 35kDa monomeric protein to 
assemble as a tetramer is expected to affect its enzyme activity. Deamidation of L- 
asparaginase was first observed for the Escherichia coli enzyme (EcA) using isoelectric 
focusing (IEF) in the 1970s (Laboureur et al., 1971a; Laboureur et al., 1971b), where it 
was noted that the change in isoelectric point (pI) had no apparent effect on enzyme 
activity. Deamidation of EcA was also studied by other researchers (Wagner et al., 1969) 
who investigated enzyme isoforms using electrophoresis and amino acid analysis. More 
recently, researchers have used two-dimensional gel electrophoresis to separate post- 
translationally modified forms (including deamidated forms) of EcA and ErA (Bae et al., 
2011). However, in all of these studies, the effect of L-asparaginase deamidation was only 
examined in a crude, qualitative way. Prior to the programme of research detailed in this 
thesis, there has been no systematic study of the effects of deamidation on L-asparaginase 
for biopharmaceutical use. 
 
 
 
 
 
1.4 Protein Degradation by Aggregation 
 
Protein aggregation is another common phenomenon affecting protein structure and 
function both in vivo (e.g., in amyloid plaque formation in Alzheimer’s disease and as a 
result of macromolecular crowding) and in vitro during biopharmaceutical production. 
Protein aggregation may be reversible or irreversible, and aggregates may be ordered (e.g. 
amyloids) or amorphous (such as inclusion bodies) (Fink, 1998). Aggregates may range in 
size from dimers (two proteins or protein assemblies) to large, insoluble aggregates of 
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thousands of subunits. They may be held together by covalent means (disulphide bonds), 
hydrophobic interactions, or electrostatic interactions. Although aggregates may retain 
functional or enzymatic properties, more commonly protein aggregation alters protein 
biological function (Invernizzi et al., 2012; Zhou et al., 2008). 
Protein aggregates may be classified and categorised according to size. Two of the 
categories of interest are small aggregates (with mean diameters of nm or tens of nm) and 
large aggregates including sub-visible particulates (SbVP) (Rathore and Rajan, 2008) with 
mean diameters in the low-micron range. SbVP are usually insoluble aggregates that 
cannot be detected by the human eye. In the context of biopharmaceutical  protein 
products, the presence and number of sub-visible particulates (SbVP) is an important 
factor to quantify and understand. This is particularly true with regard to parenteral 
(injectable) biopharmaceutical products such as ErA, where after clinical administration, 
SbVP may readily interact with human tissues and the immune system. 
In order to avoid the possibility of such deleterious effects, formation of protein aggregates 
in biopharmaceutical products such as ErA must be understood and controlled. Repeated 
freezing and thawing of ErA in water is known to generate a degree of small, soluble 
aggregates detectable by size-exclusion chromatography (SEC) (Jameel et al., 1995; 
Jameel et al., 1997). Lyophilisation, a process that is used in ErA formulation to remove 
water from the protein matrix and enhance stability, must be regarded as a potential 
aggregation-inducing step (Lueckel et al., 1998) requiring further analysis with respect to 
SbVP. Multi-subunit proteins, such as the tetrameric 140kDa (35kDa per subunit) L- 
asparaginase, may also face issues during lyophilisation such as loss of quaternary 
structure and possible loss of activity (Hellman et al., 1983; Ward et al., 1999). The 
degree to which aggregation may occur in reconstituted lyophilized drug product (DP) 
formulations varies from protein to protein, and the degree of aggregation may be reduced 
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or lowered by additions of excipients such as sucrose or trehalose (Adams 1991; Arakawa 
 
et al., 1993). 
 
Concerns over the potential for undesired immunogenic reactions from SbVP in parenteral 
products (Rosenberg 2006; Carpenter et al., 2009) has led to further study in this area in 
the past few years. Early research in this area established a relationship between IFN-α 
aggregates and levels of anti-IFN-α antibodies in murine models, suggesting that 
aggregates were undesirable from an immunogenicity perspective (Braun et al., 1997). Of 
particular interest is the size range between 2 and 10µm; however the measurement of 
SbVP in this range is a technically challenging and evolving area for both regulators and 
industry (Carpenter et al., 2009; Singh et al., 2010). Normally for routine quality-control 
testing of biologic products, the light obscuration (LO) technique is applied, but this is not 
ideal for the 2 - 10µm range for biologic products with translucent protein SbVPs (Narhi 
et al., 2009; Cao et al., 2009). One difficulty in the measurement of protein aggregates is 
that no one sizing technique is suitable across the entire spectrum from the 
angstrom/nanometer level up to microns (Narhi et al., 2009), with the 2 - 10µm range 
particularly troublesome. Researchers have also measured protein aggregates using both 
Dynamic Light Scattering (DLS) and Resonant Mass Measurement (RMM), but these 
techniques are more applicable to particles in the smaller 20 – 1000nm size range (Panchal 
et al., 2014). A newer technique for measurement of SbVP is flow-imaging microscopy 
(FIM) which has the capability to classify particulate matter as well as provide size 
distributions and particulate counts (Sharma et al., 2007; Sharma et al., 2010). FIM 
algorithms can be produced in order to classify particles based on image characteristics 
such as shape or translucency (Weinbuch et al., 2013; Strehl et al., 2012). Prior to the 
research described in this thesis, no FIM studies of ErA had been described in the 
literature.  Furthermore, to the best of my knowledge and that of the peer reviewers for my 
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manuscript, the clinical impact of SbVP had not been described in the literature for any 
biopharmaceutical protein product. 
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2.1 SUMMARY OF THE RESEARCH 
 
2.2 Aims of the Research Programme 
 
Due to their complex nature, proteins may degrade into related variants via a number of 
non-enzymatic means, such as deamidation, aggregation and oxidation. This is 
particularly true when manufacturing proteins at large scale for biopharmaceutical use. 
The degraded protein variants may or may not have the same stability, efficacy and/or 
clinical impact as the parent compound. Often, proteins used as biopharmaceuticals may 
contain a small proportion of degraded variants at the time of administration. In 
biopharmaceutical development it is usually assumed that these degraded variants are 
undesirable or deleterious to clinical use, which is a common conclusion (D’Souza et al., 
2012; Torosantucci et al., 2013) but may not always be the case (Haberger et al., 2014). 
Thus, a common problem in the development of biopharmaceutical proteins is the lack of 
understanding around the implications of degradation. 
This problem is relevant to the enzyme L-asparaginase from the plant pathogen Erwinia 
chrysanthemi (ErA, or Erwinase), which is used as a treatment for acute lymphoblastic 
leukaemia (ALL). The overall programme of research described here aims to deepen the 
understanding of the robustness of ErA production, the degradation processes that the 
enzyme may undergo, and how those degradation processes impact the safety and efficacy 
of the product in its intended therapeutic use.  In particular, the study aimed to: 
1. Develop an understanding of the effect of deamidation on ErA, including novel 
methods for measuring deamidation in ErA, and the potential causes of 
deamidation during ErA manufacture. 
2. Understand how ErA deamidation at the most labile sites in the molecule affects 
the structure and function of the enzyme. 
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3. Perform a systematic study of the effect of subvisible ErA aggregates in the 2- 
10µm size range on the onset of allergic reactions observed after ErA clinical use. 
4. Provide a rational framework to understand the variability of enzyme produced by 
the normal ErA manufacturing process, as well as demonstrating the potential for 
the application of this framework to other biopharmaceutical products. 
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2.3 Summary of the Published Work 
 
The research programme described above was carried out at Public Health England (PHE, 
formerly the Health Protection Agency) at Porton Down, UK between 2010 and 2014. 
The output from this programme includes a total of five peer-reviewed primary research 
publications, which are listed in Table 1. A brief summary of the scope of each 
publication is provided in the sub-sections below. 
 
 
 
Table 1.  List of publications. 
 
 
Reference 
Number 
Reference 
1 Gervais D, King D. Capillary isolelectric focussing of a difficult-to- 
denature tetrameric enzyme using alkylurea-urea mixtures. Analytical 
Biochemistry 2014; 465:90-95. 
2 Gervais D, Foote N. Recombinant deamidated mutants of Erwinia 
chrysanthemi L-asparaginase have similar or increased activity compared 
to wild-type enzyme.  Molecular Biotechnology 2014; 56(10):865-877. 
3 Gervais D, Corn T, Downer A, Smith S, Jennings A. Measurement of 
subvisible particulates in lyophilised Erwinia chrysanthemi L- 
asparaginase and relationship with clinical experience. AAPS J 2014; 
16(4):784-790. 
4** Gervais D, O’Donnell J, Sung M, Smith S. Control of process-induced 
asparaginyl deamidation during manufacture of Erwinia chrysanthemi L- 
asparaginase.  Process Biochem 2013; 48(9):1311-1316. 
5* Gervais D, Allison N, Jennings A, Jones S, Marks T. Validation of a 30- 
year-old process for the manufacture of L-asparaginase from Erwinia 
chrysanthemi.  Bioproc Biosyst Eng 2013; 36(4):453-460. 
* Later referred to as Gervais et al., 2013a. 
** Later referred to as Gervais et al., 2013b. 
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2.2.1 Quantitative Measurement of Deamidation in ErA (Paper 1) 
 
Paper 1 (Gervais and King, 2014) describes a novel method developed to assess the extent 
of ErA deamidation using capillary isoelectric focussing (cIEF). As a quantitative 
method, cIEF is a good tool for the analysis of deamidation, as this PTM results in a shift 
in the protein isoelectric point (pI). However, it is important in these applications that the 
protein is fully denatured to ensure that all the amino acid residues, including those that 
are buried in the native state, contribute to the measured pI. Typically in cIEF, 8M urea is 
used to denature the protein, but in the case of ErA, a stronger denaturant was found to be 
required. Denaturants used in both gel IEF and cIEF must be non-ionic in nature, since 
the presence of salts in IEF cause the electrical current to increase. High concentrations of 
salts (or ionic chaotropic denaturants such as guanidinium hydrochloride) cause such an 
increase in current that the electrophoretic medium (capillary or gel) may be destroyed. 
Substituted alkylureas were identified from the literature (N-methylurea, N-ethylurea, etc) 
which had been shown to be more powerful denaturants than urea alone (Kumar et al., 
2014; Poklar et al., 1999). Alkylureas had not previously been utilised in cIEF 
applications, and our paper demonstrated that they can be used in a robust and 
reproducible assay for ErA deamidation. The method we reported can be widely 
applicable to the study of proteins that do not easily denature in urea. 
 
 
 
2.2.2 Effect of Deamidation on ErA Structure and Activity (Paper 2) 
 
Understanding the impact of deamidation on ErA was critical to the success of this 
research programme. Detailed study of the effects of deamidation was not possible using 
routine ErA samples from production, as they may contain a maximum of only 5 – 10% 
deamidated material.  Therefore, a programme of work was undertaken to express, purify 
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and fully characterise three ErA mutants which contained genetically engineered 
deamidated residues, and this research is documented in Paper 2 (Gervais and Foote, 
2014). Multiple techniques were used to characterise the thermal and chemical stability of 
variants, including denaturation, isoelectric focusing, HPLC, SDS-PAGE, circular 
dichroism, and in silico structural analyses. As part of this work, an enzyme purification 
strategy was developed, using modifications of reported substrate-affinity chromatography 
techniques (Kotzia and Labrou, 2005; Lee et al., 1989). This strategy proved to be 
successful, and allowed a better understanding of the effect of deamidation at multiple 
sites, the relationship of deamidation to ErA enzyme kinetics, and the relationship between 
deamidation and enzyme structure and stability. Certain mutations rendered an ErA 
protein that closely resembles a homologue of high amino acid sequence conservation 
(Erwinia carotovora L-asparaginase, or EwA). The similarity extends to the stability, the 
hydrogen bonding network near the mutations and the enzyme kinetic properties of the 
proteins (Papageorgiou et al., 2008; Gervais and Foote, 2014). 
 
 
 
2.2.3 Effect of Aggregation on ErA Pharmaceutical Efficacy (Paper 3) 
 
Protein aggregation is another common phenomenon that can alter the efficacy of 
biopharmaceuticals. Aggregates of enzyme products, such as ErA, may have reduced 
activity and efficacy due to masking of the enzyme’s active site. Sub-visible aggregates, 
in the size range between 2 and 10µm, have been further hypothesised as being implicated 
in undesired immunogenicity (and allergic response) to biopharmaceuticals (Carpenter et 
al., 2009, Cao et al., 2009). Therefore, in the research described in Paper 3 (Gervais et al., 
2014), ErA aggregation was studied as another mechanism with the potential for adverse 
effects   towards   efficacy  and   potency.   Using   flow-imaging  microscopy,   the   ErA 
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aggregation profile in the sub-visible size range was characterised. The research went on 
to relate the aggregation data to the effectiveness in the clinical use of the enzyme. Using 
statistical analyses it was demonstrated that the incidence of allergic events, such as 
hypersensitivity, was essentially independent of the level of sub-visible ErA aggregates in 
the materials used in the clinic. Studies such as this, aiming to define the relationship 
between protein aggregates and allergic response, had not previously been documented in 
the literature for any biopharmaceutical product. 
 
 
 
2.2.4 Control of Deamidation During ErA Manufacture (Paper 4) 
 
Control of in-process deamidation is a critical part of manufacturing any 
biopharmaceutical product. Deamidation of asparagine residues is mediated by a non- 
enzymatic reaction at pH values greater than 7, and the product of the reaction is either an 
aspartic acid or isoaspartate residue. In addition to the change in the net charge of the 
protein, the substitution of asparagine for the acidic aspartic acid residue may have an 
impact on protein structure and function. In the research described in Paper 4 (Gervais et 
al., 2013b), the causes of ErA deamidation during manufacture were investigated. ErA 
contains one asparagine residue that is theoretically prone to deamidation due to the short 
sequence, NG motif (Tyler-Cross and Schirch, 1991). However, the NG motif is only 
surface-exposed when the tetramer is disassembled; it is normally buried within the 
tetrameric structure and thus protected from deamidation when the quaternary structure is 
intact. During the course of this research, the freezing and thawing of Erwinia 
chrysanthemi cells was found to cause partial and temporary disassembly of the tetrameric 
ErA, exposing the labile asparagine residue and making it susceptible to deamidation 
during cell lysis. It was found that allowing time for the tetramer to re-form after cells 
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thaw protected the labile asparagine residue of the NG motif, thus preventing protein 
deamidation. 
 
 
 
2.2.5 Consistency of ErA Manufacturing (Paper 5) 
 
The overall research programme was reliant on the consistent and reproducible production 
of ErA enzyme. Therefore, in the research described in Paper 5, Gervais et al., 2013a 
(which was the first paper chronologically), it was demonstrated that ErA is made using a 
robust and reproducible process. Because the quality of the enzyme is dependent on its 
quaternary structure, as ErA is a tetrameric enzyme (four identical 35kDa subunits) that 
must be fully assembled in order to be active, it was important to prove that the subsequent 
studies on ErA degradation were not dependent on how the protein samples were purified. 
The ErA manufacturing process is an established, long-standing process, so the approach 
to validating the process had to be different compared with new biopharmaceutical 
entities. Communication of this non-standard, alternative approach to process validation 
for older products was the main aim of this paper. 
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2.3       Contributions of the Candidate 
 
A summary of the candidate’s contributions to each of the five papers which comprise the 
published work is provided in Table 2. Statements for each of the papers, signed by all co- 
authors and indicating agreement with the candidate’s contributions, are also available in 
Appendix 1.        
Table 2.  Contributions of the Candidate 
 
 
Contribution of Candidate 
Co-authors 
in 
agreement 
Paper 1. Capillary isoelectric focussing of a difficult-to-denature tetrameric 
enzyme using alkylurea-urea mixtures. 
 
David Gervais had the lead role in this research. He identified the need for 
better analytical tools for ErA deamidation measurements, identified and 
procured the instrumentation, and proposed alkylureas as cIEF-compatible 
denaturants. He developed the methods, researched the literature, performed the 
experiments, analysed the data, wrote the manuscript and corresponded with 
reviewers. The co-author contributed some of the analyses with the instrument 
and methods to integrate the electropherograms. 
D King 
Paper 2. Recombinant deamidated mutants of Erwinia chrysanthemi L- 
asparaginase have similar or increased activity compared to wild-type enzyme. 
 
David Gervais had the lead role in this research. He proposed the generation of 
recombinant deamidated variants of ErA using heterologous protein expression 
in E. coli. David Gervais designed the variant constructs, and performed the 
protein expression, purification and characterisation including in vitro techniques 
and in silico structural analyses. He also analysed the data and wrote the 
manuscript. David Gervais served as the lead author and addressed the 
reviewers’ comments. N Foote contributed the enzyme activity and Km 
measurements. 
N Foote 
Paper 3. Measurement of subvisible particulates in lyophilised Erwinia 
chrysanthemi L-asparaginase and relationship with clinical experience. 
 
David Gervais had the lead role in this research. He determined the 
instrumentation necessary to make the aggregation size measurements and 
played a lead role designing the methods and in implementation of the technique. 
He directed the research and analysed all the data, wrote the manuscript, and 
served as corresponding author with the journal reviewers. Co-authors provided 
clinical data, provided some of the analytical runs on the instrument, and helped 
with manuscript revision. 
T Corn 
 
A Downer 
S Smith 
A Jennings 
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Contribution of Candidate 
Co-authors 
in 
agreement 
Paper 4. Control of process-induced asparaginyl deamidation during 
manufacture of Erwinia chrysanthemi L-asparaginase. 
 
The paper contains a summary of the contributions to this work within the text of 
the published manuscript. David Gervais had the lead role in this work, with the 
initial proposal that thaw time and deamidation may be related. He designed the 
research, performed the research and the research experiments, analysed the 
data, and wrote the manuscript. He also responded to reviewers’ comments as 
corresponding author. Co-authors provided analytical methods and supported 
data evaluation. 
J O’Donnell 
M Sung 
S Smith 
Paper 5. Validation of a 30-year-old process for the manufacture of L- 
asparaginase from Erwinia chrysanthemi. 
 
David Gervais had the lead role in this manuscript. Although the data were 
generated by the Erwinase manufacturing team, David Gervais influenced the 
validation strategy, analysed the data, and wrote the manuscript. He also 
responded to reviewers’ comments as corresponding  author.  Co-authors 
provided analyses of historical data, supported data evaluation, and supported 
manuscript revision. 
N Allison 
A Jennings 
S Jones 
T Marks 
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3.1 CRITICAL APPRAISAL OF THE PUBLISHED WORK 
 
The critical appraisal of the published work includes an assessment of the contribution to 
knowledge offered by each work (Section 3.1), as well as a detailed analysis of each 
publication grouped by sub-topic (Section 3.2). 
 
 
 
3.2 Assessment of Candidate’s Contribution to Knowledge 
 
The published work contributes to the present state of knowledge in the field in several 
different ways: 
 
1. It provides a description of a set of mutants of Erwinia chrysanthemi L- 
asparaginase in terms of structural, kinetic and physicochemical properties. 
Observed differences in the kinetic properties are related to the structural 
characteristics at the mutation points in the molecule. These types of findings 
are of great interest in the structural biology, protein chemistry and 
biotechnology areas, and may help efforts to engineer L-asparaginase variants 
that are more stable, more active and which persist longer during clinical use. 
 
2. It provides an understanding of the consequences of degradation of Erwinia 
chrysanthemi L-asparaginase by two of the most common means: deamidation 
and aggregation. Typically in development of protein biopharmaceuticals, the 
products of these degradation processes are assumed to have a negative impact 
on enzymatic function, stability or clinical use. However, in this work it is 
shown that these degradants are not necessarily detrimental, and that these 
product-related  variants  should  be  studied  using  orthogonal  techniques  to 
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establish their true properties.   The methodology used in this work should be 
widely applicable to the study of proteins being used as biopharmaceuticals. 
 
3. To the best of our knowledge, it provides the first data set known in  the 
literature relating protein aggregate levels to immunogenicity. The topic of 
undesired immune response in protein biopharmaceuticals is a topic of great 
interest. However, no other paper published to date seems to have attempted to 
understand these potential immune-mediated reactions in a causal way. 
 
4. It contributes a novel, improved method for routine measurement and 
quantitation of deamidated protein species using alkylureas and capillary 
isoelectric focussing. The use of alkylureas as powerful denaturants was 
reported in the literature previously, but application of these compounds to 
quantitative capillary electrophoretic techniques was not known. The agreement 
of the data with isoelectric point predictions using pKa values provides good 
validation of the technique presented in the published work. Capillary 
electrophoresis is an important technique for detection and quantitation of 
protein species. The published work provides the community with a new and 
useful tool for analysis of deamidated variants in protein preparations. 
 
5. It contributes a framework for proving the robustness of older protein 
manufacturing processes through validation. The principles of validation are 
usually applied to new products in development, and their application to older 
products presents a unique set of challenges not covered in the literature prior to 
this paper. 
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3.3 Critical Analysis of the Published Work 
 
3.3.1 Effect of Deamidation on ErA 
 
Prior to the start of the research programme, there was little information available on the 
measurement or effects of post-translational modifications (such as deamidation) on 
Erwinia chrysanthemi L-asparaginase. However, with respect to ErA, there was already a 
rich body of literature in the public domain. Some of the relatively recent references on 
ErA include publication of the crystal structure of the ErA enzyme (Lubkowski et al., 
2003; Aghaiypour et al., 2001; Miller et al., 1993) and a closely related variant 
(Papageorgiou et al., 2008). Further published studies on ErA include cloning and 
expression of recombinant forms of the enzyme (Kotzia and Labrou, 2007), and use of 
mutations to engineer thermal stability (Kotzia and Labrou 2009) and resistance to 
proteolytic cleavage (Kotzia et al., 2007). However, none of these studies included 
research into the deamidation (or aggregation) of the enzyme. 
Early research on the closely-related Escherichia coli L-asparaginase (EcA) (Laboureur et 
al., 1971a; Laboureur et al., 1971b; Wagner et al., 1969) may have identified the existence 
of deamidated forms of the enzyme, but they were only detected, and not characterised. A 
more recent reference (Bae et al., 2011) included a consideration of EcA and ErA 
deamidation in the context of all post-translational modifications (PTM) using two- 
dimensional gel electrophoresis and mass spectrometry analyses of commercial 
preparations. However the work presented was qualitative, not quantitative for 
deamidation (or any other PTM). The impact of any specific deamidation site (or PTM) on 
the properties of the enzyme was also not considered in the paper by Bae et al. (2011). 
Three of the papers presented in this thesis are relevant to the topic of ErA deamidation 
and significantly extend this area of knowledge. The published work includes an analysis 
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of the causes of ErA deamidation during manufacture (Gervais et al., 2013b), a full 
characterisation of the deamidated forms of the enzyme (Gervais and Foote, 2014), and 
novel methods for measurement of ErA deamidation (Gervais and King, 2014). 
Deamidation is a primary structure change (a change at the amino acid sequence level) and 
is perhaps the most common PTM observed. However, measurement of protein 
deamidation is difficult. Most often, mass spectrometry (MS) is utilised (Robinson et al., 
2006) with most modern MS instruments able to resolve the +1Da difference that results 
from a deamidation event (Rivers et al., 2008). Although MS can detect deamidation, 
specialised and expensive equipment is required for such analyses and the technique is not 
always suitable for routine protein measurements, particularly in a biopharmaceutical 
production setting. Use of MS to measure deamidation may be further complicated during 
sample workup by creation of deamidated artifacts not originally present in the analyte 
sample. The protein tertiary structure has been shown to play a role in the rate of 
deamidation, with buried residues protected from nonenzymatic deamidation (Rivers et 
al., 2008). Therefore, depending on the proteolytic digestion, denaturation, and sample 
workup conditions used prior to mass spectrometry analyses, significant artefacts may be 
introduced as protected Asn residues become exposed to solvent. 
Another alternative approach to deamidation measurement is to use assays based on the 
enzyme protein L-isoaspartyl methyltransferase (PIMT). PIMT preferentially methylates 
isoaspartate residues in the presence of S-adenosyl-L-methionine, facilitating conversion 
of the isoaspartate back to aspartate (Johnson et al., 1987). A commercial assay using this 
principle and HPLC has been developed (Johnson and Aswad, 1991) for the detection of 
isoaspartate in samples of biopharmaceutical proteins. Isoaspartate residues do not occur 
naturally in proteins on translation, but may occur as the product of a racemisation 
reaction involving Asp residues.  Since the product of an asparaginyl deamidation event is 
35  
a mixture of isoaspartate and aspartate residues in a distribution of approximately 2:1 
isoAsp to Asp (Aswad et al., 2000), the assay is only an indirect measure of protein 
deamidation. However, in the case of ErA, this commercial  assay  (Promega, 
Southampton, UK) was attempted on a number of occasions without success (data not 
shown), possibly due to the buried nature of the labile Asn residues in the enzyme. 
Consequently, alternative means of assessing ErA deamidation were required. The assay 
described in the first paper of the published work is based on a change in net charge, a 
further property of deamidated proteins. In this paper, it is shown that ErA deamidation 
can be quantified using capillary isoelectric focussing (cIEF) (Paper 1, Gervais and King, 
2014). cIEF methods are more suitable for quantitative analysis than gel-based 
techniques, as the detection by UV absorbance is more sensitive than gel densitometry. 
The cIEF outputs, or electropherograms, can be integrated to provide quantitative 
information in the same way as HPLC traces. The cIEF approach was an improvement on 
the previously-published two-dimensional gel electrophoresis method for ErA (Bae et al., 
2011) which used a gel-based IEF separation and was not quantitative. The novel cIEF 
technique utilises mixtures of urea and N-ethylurea to provide a level of protein unfolding 
appropriate for measurement of the impact of charge over the entire 327 residue length of 
the ErA monomer. This strategy, coupled with the quantitative sensitivity of  cIEF, 
allowed an assessment of the levels of PTMs present in ErA samples from the 
manufacturing plant. In Paper 1, it is demonstrated through forced-degradation 
experiments that the assay is appropriate for the detection of deamidated variants if they 
are present. The method should be broadly applicable to other enzymes and proteins 
beyond ErA. 
The cIEF approach, however, is not without drawbacks. One particular point is that ErA 
acidic species (peaks with a pI less than the main peak pI of 7.35) cannot be definitely 
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classed as deamidation, using this assay. Rather, it is appropriate to say that this method is 
capable of detecting deamidated residues if they are present in ErA samples, as 
demonstrated in Paper 1 with forced degradation and recombinant mutants. These 
approaches provided assurance that deamidation could be detected, and that the low values 
of ErA acidic species observed in routine manufacturing samples show that deamidation 
levels may be very low (1.0 – 3.5% of total UV-absorbing species). With this important 
issue of data interpretation clarified, it can be argued that the MS approach is superior, as 
the mass signals obtained enable the analyst to definitively classify the nature of any 
PTMs present, including deamidation.   The cIEF approach should therefore be regarded 
as a convenient method for high-throughput situations where there are numerous samples, 
or where expensive MS equipment is not available. 
While measurement of deamidation is an important factor to consider, so too is the effect 
of deamidation on the characteristics and performance of the enzyme. The second paper 
from the published work (Paper 2; Gervais and Foote, 2014) describes the production and 
characterisation of recombinant ErA mutants with engineered deamidation sites. This 
paper has been cited (Pokrovskaya et al., 2014) by investigators characterising mutant 
versions of Rhodospirillum rubrum L-asparaginase. In general, the production of 
recombinant deamidated variants had been described in the literature (e.g., Takata et al., 
2008) but not in the context of studying the impact on biopharmaceutical properties or 
efficacy. Furthermore, the ErA mutants generated and studied in this research programme 
had not been previously described. Production of recombinant deamidated variants is a 
good strategy to help understand the impact of this PTM on the structure and function of 
the enzyme. However, one particular drawback of this approach is the inability to 
genetically engineer variants incorporating isoAsp residues. As discussed above, isoAsp 
residues are a normal product of non-enzymatic deamidation reactions.  If an isomerase 
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were available, such as an aspartate racemase, that had activity on protein-bound amino 
acid residues (instead of free, solvated amino acids), it may have been possible to further 
study the influence of isoAsp versus Asp deamidation products, but this is beyond the 
scope of the work presented here. 
Prior to generation of the ErA recombinant deamidated mutants, it was expected that the 
mutants would display inferior properties compared with the wild type (WT) enzyme. The 
published work (Gervais and Foote, 2014) includes a structural and functional description 
of how the deamidation events change ErA. Interestingly, it was discovered that the 
mutations studied (N41D, N281D and a double mutant containing both substitutions) 
increased, rather than decreased, the catalytic performance of the enzyme (expressed as 
kcat). Furthermore, the N281D mutation was observed to impart an increase in the 
Michaelis constant Km compared with WT (denoting a decrease in substrate affinity). The 
properties of ErA mutants carrying the N281D mutation were similar to those of the wild- 
type L-asparaginase (EwA) from the related specie Erwinia carotovora as described by 
Papageorgiou et al. (2008), in terms of thermal stability and function (i.e., specificity, 
catalytic constants, and activity). A structural analysis in silico was carried out using the 
CHIMERA software package (Pettersen et al., 2004) (Figure 2) by comparing published 
structures for ErA (PDB: 1HG1, 1O7J) with the published structure for EwA (PDB: 
2JK0). This analysis revealed that hydrogen bond formation in the regions of interest 
around the ErA N281D site had also changed to be more akin to that of the published EwA 
structure. The agreement of both the empirical and in silico results with published data 
from a closely related enzyme with high sequence identity to ErA, provides a compelling 
validation of the data discussed in Paper 2. 
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Figure 2.  Structural comparison of L-asparaginase from Erwinia chrysanthemi (ErA) with Erwinia 
carotovora (EwA).  Images were generated using CHIMERA software and PDB entries 1HG1 and 2JK0. 
(A) Tetramer structure with one subunit shown in green (ErA) or blue (EwA),  (B) Comparison of 35kDa 
subunit structure with the N and C termini indicated,  and (C) Comparison of hydrogen bonding 
opportunities around N281/D281  for WT and mutant ErA and S281 (EwA) with the A chain depicted in 
green, the C chain depicted in pink, and the location of inter-chain bonds labelled a, b, c, or d.  The N281D 
mutation in ErA causes the loss of a hydrogen bonding opportunity (labelled ‘a’) between the N281 amide 
and the peptide bond carbonyl group in A171 on the opposing chain.
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One interesting observation regarding the research described in Paper 2 was that one of the 
mutations (N281D) had an effect on both the thermal and denaturing stability of the 
enzyme. For thermal stability, variants not carrying the N281D mutation retained 
approximately 100% of initial activity at temperatures up to 60°C, while those with the 
N281D deamidation showed a decrease in activity at temperatures above approximately 
45°C. Similarly, ErA without the N281D mutation retained activity after exposure to all 
concentrations of urea up to 7.2M, where those enzymes with the N281D mutation 
displayed reduced activity after exposure to approximately 1.8M urea and higher. Protein 
stability is a major consideration with regard to the production of biopharmaceuticals, and 
a lowering of protein stability may be a concern to manufacturers, developers and 
regulators. However, it should be noted that ErA is an unusually stable enzyme and that 
the stability change effected by the N281D deamidation also only occurs during higher- 
than-normal temperatures (>45°C) and conditions (>1.8M urea). Restriction of handling, 
storage and clinical administration conditions may be the only steps required to limit 
stability problems due to ErA deamidation, and this understanding should be considered as 
one of the useful outputs of this research programme. 
Although production of the recombinant deamidated ErA mutants was an acceptable 
strategy that provided convincing and useful results, it should be noted that alternative 
strategies exist and could have also been explored. The inability to genetically engineer 
isoAsp residues, as discussed above, is one drawback of the chosen methodology. 
Another approach would have involved crystallisation of purified enzyme from the 
recombinant mutants and comparison of mutant x-ray structures with that of the wild-type, 
in order to gain further structural insight. This strategy should have been more 
informative than the circular dichroism (CD) and in silico analyses used in Paper 2, but the 
strategy was not pursued due to lack of access to the facilities needed to complete such 
40  
studies. However, due to the good agreement between the published work and previously 
published studies (Papageorgiou et al., 2008) on structure and function of the recombinant 
deamidated ErA variants and wild-type EwA, it could also be argued that the 
crystallisation approach was superfluous in this instance. A further alternative approach 
would have been to make mutants of ErA deamidated at different sites to N41 and N281; 
however, these latter sites were chosen based on their theoretical propensity to deamidate 
based upon literature data (Tyler-Cross and Schirch, 1991) and were therefore thought to 
represent the most likely scenarios in ErA degradation. Finally, the research described in 
Paper 2 could have been approached from the point of view of intentionally introducing 
deamidation into the WT protein (e.g., in forced-degradation studies); however, under this 
strategy, it would have been impossible to direct the deamidation to selected sites of 
interest. With these alternatives in mind, it seems reasonable to conclude that  the 
approach used in this research programme (characterisation of selected recombinant 
deamidated mutants) was appropriate given the research questions under investigation. 
In addition to measurement of deamidation and the effects of deamidation, the research 
programme also focussed on the causes of deamidation during ErA manufacture. This is 
the subject of the fourth paper (Paper 4; Gervais et al., 2013b), in which deamidation- 
labile ErA residues were identified, along with the point in the manufacturing process 
where they were most susceptible. Chronologically, this part of the research programme 
was conducted prior to the research detailed in Papers 1 and 2, so that the cIEF method 
was not available, nor was the understanding of the impact of deamidation. The 
deamidation methods that were available included ion-exchange HPLC (IEX), capillary 
zone electrophoresis (CZE) and a limited subset of peptide-map LC-MS. Using size- 
exclusion chromatography (SEC) it was determined that ErA tetramers fall apart after 
freeze-thaw and take some time to reassociate.   Allowing a longer freeze-thaw time is 
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beneficial, as the monomers can then reassemble into tetramers thereby protecting one of 
the theoretically most deamidation-prone residues (N281). 
In terms of a critical evaluation of Paper 4, there are obvious parts of the strategy that 
could have been approached differently. Use of the superior cIEF technique would have 
been preferable compared with IEX and CZE, but at the time cIEF was not available. 
Furthermore, availability of recombinant deamidated mutants would have been very 
advantageous, as the mutants could have been used in spiking and proof-of-concept 
experiments directed at particular residues. In hindsight, deamidated versions of peptides 
from the mapping assay used in Paper 4 (e.g., a synthetic peptide TGDGIVPP…) would 
have also provided a good control mechanism for the data described in the paper. 
However, it should be noted that the deamidated mutants described in Paper 2 have been 
subjected to the same tryptic digest and peptide mapping assay (data of P. Kanda, PHE, 
not shown or published) and found to behave as expected, i.e., deamidation in the mutant 
ErA variants N41D and N281D is easily detected using MS. 
In summary, the published work extends the state of knowledge on the effects, 
measurement and causes of ErA deamidation. Little was described in the literature on ErA 
deamidation before the research programme was undertaken. Although alternative means 
could have been used to describe the effects, causes and quantitation of ErA deamidation, 
the published data obtained compare well with that in the literature from closely-related 
enzymes with high identity to ErA. Furthermore, the methods used in the published work 
are broadly applicable to other biopharmaceutical protein products. 
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3.3.2 Effect of Aggregation on ErA 
 
Protein aggregation is another common problem with respect to the stability of protein 
biopharmaceuticals such as ErA. Studies of the effect of ErA freezing and thawing cycles 
on aggregation have previously been described (Jameel et al., 1995; Jameel et al., 1997), 
but these studies focussed on small, soluble aggregates detectable by SEC, such as ErA 
dimers (two 140kDa tetramers held together) or trimers. Aggregates may also take the 
form of much larger particles consisting of many subunits, with sizes up to the micron size 
range or larger. Prior to the start of this research programme, no studies of larger, sub- 
visible ErA aggregates in the 2 – 10µm size range (sub-visible particulates or SbVP) had 
been described in the literature. These larger aggregates were previously postulated to play 
a role in undesired immune-mediated reactions to some biopharmaceutical treatments. For 
example, one hypothesis is that allergic reactions may result from immune system cells 
encountering aggregates containing ordered or partially-ordered arrays of proteins 
(Carpenter et al., 2009). However, it is important to note that the relationship between 
SbVP and undesired immunological reactions was only proposed in Carpenter et al. 
(2009), and prior to this research programme no data existed to back up this proposal for 
ErA or any other biopharmaceutical product. 
The study of SbVP for other proteins was known in the literature (Singh et al., 2010; Cao 
et al., 2009) and the severity of allergic reactions to L-asparaginases including ErA had 
also been studied (e.g., Woo et al., 2000) but no study had been published regarding any 
potential link between the two phenomena. Therefore, the published work presented here 
(Paper 3; Gervais et al., 2014) represents not only the first study of its kind for ErA, but 
also for any protein in clinical use. The levels of sub-visible aggregates were found to 
have no relationship to the incidence of allergic reactions during clinical use in humans, an 
important initial step for this field of study. 
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The data presented in Paper 3 do support the argument that SbVP levels and allergic 
reaction appear unrelated. However, several factors should also be considered in a critical 
evaluation of this work, including the methodology in the SbVP measurements as well as 
the approach to the clinical data. In the paper, SbVP data from two methods (light 
obscuration or LO, and flow-imaging microscopy, or FIM) are compared. Many lots of 
ErA lyophilised drug product (DP) were measured using the two techniques. Ideally, 
these two measurements would have been made together in real-time on the same samples, 
to separate any temporal or stability-based effects. However, these measurements were 
made at different times due to logistical and practical issues. The LO measurements were 
made at the time of release of each DP batch to the clinical market, while the FIM 
measurements were made shortly prior to writing the manuscript for Paper 3, and in some 
cases months or years had passed between the two measurements. The reason for this is 
that LO is used as the regulatory-approved release test for ErA DP and must be conducted 
at time of release. Further, the LO measurement is carried out off-site by a third-party 
contractor, and each LO measurement requires approximately 20 vials of a given batch of 
ErA DP to be reconstituted and pooled to provide sufficient liquid volume for the 
instrument. At the time of the FIM measurements, it was not possible to go back and re- 
acquire LO data for each DP batch, as sufficient vials were no longer available for this. 
The FIM instrument can handle one vial or even partial vials to provide a measurement, 
but it was not available at the time the LO data were acquired. Another factor is that due 
to the pooling of vials required for each LO analysis, vial-to-vial variability in the 
measurements is minimised, while in the FIM analysis inter or even intra-vial differences 
can be measured.  These pooling factors are discussed in Paper 3. 
Apart from the logistical issues regarding the LO and FIM measurements, the relationship 
of these SbVP data with the clinical data must be considered.   In Paper 3, a DP lot 
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containing relatively high levels of 2-10µm SbVP was chosen to evaluate for clinical 
experience versus the rest of the DP lots. Although the lot chosen for evaluation had 
relatively high levels of SbVP by both LO and FIM, it was not the highest measurement 
made for either technique. This is due to the fact that there was poor agreement between 
the LO and FIM data sets, as discussed in Paper 3. Analysis of the clinical data against 
other DP lots (such as those with the highest FIM or highest LO numbers), to determine 
any differences in the correlation, was not carried out due to the lack of access to the raw 
clinical data. 
Simultaneous acquisition of the data (LO and FIM), as postulated above, may have 
improved the agreement of the two SbVP measurements, but the lack of agreement could 
also be due to basic differences in the particle sizing methodology. LO is a light- 
obscuration technique which relies on protein particles blocking the passage of light 
through a flow cell. Although LO is an industry-standard technique for protein 
parenterals, the translucent nature of protein particulates results in some obvious 
deficiencies for LO as an analytical test. FIM is a newer technique which uses a 
microscope mounted to a vertical flow cell, coupled with a computer-based counting 
system, to image every particle that passes the field of view. In this way, FIM data can be 
sorted into types of particulates and can also theoretically provide a total count of every 
particulate present in a given sample. 
Even with the logistical (measurement timing) and empirical (lack of agreement between 
two techniques) drawbacks discussed above, this study indicates that allergic reactions 
observed during clinical use are not a consequence of ErA SbVP. Most, if not all of the 
critical points discussed above are a consequence of the fact that this study was conducted 
retrospectively, instead of in a prospective way. The clinical data and LO data were 
already  complete  at  the  start  of  the  FIM  work  and  data  analyses,  and  simultaneous 
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assessment of SbVP using multiple methods was not possible. Any future work in this 
area should consider prospective studies in order to answer some of the questions posed 
above. 
 
 
 
3.3.3 Consistency of ErA Manufacture 
 
Part of the published studies describes the work performed to demonstrate the 
reproducibility, and consistency of the ErA manufacturing process (Paper 5; Gervais et al., 
2013a). The research described in this paper was performed prior to that detailed in the 
other four papers (Papers 1-4). Paper 5 has been cited in two other publications to date 
(Keating 2013; Liu et al., 2013). 
Paper 5 was written to describe the strategy and approach of performing validation studies 
on a manufacturing process for a mature biopharmaceutical product, such as ErA. The 
situation with ErA validation was unusual, as most biopharmaceutical products undergo 
validation studies at the end of the research and development phase, just as the product is 
finishing clinical trials in humans and before marketing the drug. In the case of ErA, these 
studies were performed after the product had already been marketed for many years (apart 
from in the United States). The strategy detailed in the paper was successfully used to 
gain acceptance for the product with the US Food and Drug Administration. 
Approaching this paper from a critical point of view, it is difficult to find alternative 
strategies that could have been used. At least in part, the strategy described in the paper 
was dictated by practical and logistical considerations. For instance, many of the new 
analytical methods (such as HPLC-based methods) that were developed for the validation 
exercise were only used to analyse two ‘profiling’ batches (referred to as ‘G’ and ‘H’ in 
the paper) prior to the prospective validation exercise.  In an ideal situation, more of the 
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historical batches (‘E’ and ‘F’, for instance) could have been analysed using these 
methods, to gain more experience and useful data going forward. However, these new 
methods took some time to develop and in a practical sense, were not ready for these 
earlier batches. This, coupled with the frequency with which manufacturing batches are 
made (at present, only 2 per annum) meant that the profiling batches were limited to two. 
Biopharmaceutical validation is defined as the process of ensuring that a protein 
manufacturing process is robust, reproducible, and produces product of acceptable quality. 
In the literature, there are numerous articles about biopharmaceutical validation (e.g., 
Moran et al., 2000; Rathore and Sofer, 2012), as well as industry and regulatory 
guidances, however most, if not all, of these resources are geared toward new products in 
development. Validation of existing protein products presents a set of unique issues and 
challenges, and the published work (Paper 5) represents a strategy for approaching this 
situation. 
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4.0       CONCLUSION 
 
Biopharmaceutical proteins, including ErA, may undergo some degree of degradation 
during processing, storage and in clinical use. The degradation may occur to a smaller or 
lesser extent depending on handling and storage conditions, and may be controlled to 
some extent by imposing restrictions on these conditions. However, even small amounts 
of degraded variants may be present in protein pharmaceutical preparations, and therefore 
their impact must be assessed. Often, the impact of these species is assumed to be 
negative, due to difficulties in isolating the degraded species in a sufficient quantity to 
allow them to be studied. In this research programme, it was shown that in the case of the 
biopharmaceutical enzyme ErA, the impact of certain types of degradation is not 
necessarily negative. 
One of the main outcomes of this work is the development of alternative tools and 
strategies that can be used to assess the impact of degraded protein species in 
biopharmaceutical preparations. For instance, production of recombinant ‘deamidated’ 
enzyme is a relatively straightforward way of studying the impact of deamidation on 
protein structure and function. Rather than inferring the effect of deamidation on activity 
and pharmaceutical efficacy by comparing ErA batches with varying small percentages (5 
– 15%) of deamidated species, the effects of deamidation could be studied directly. 
Similarly, by studying the aggregation state of ErA, it was observed that a low sub-visible 
protein aggregate content can be tolerated without compromising the efficacy of ErA or 
increasing the risk of clinical hypersensitivity. Due to the obvious potential benefits these 
strategies provide, a key output of this research programme is the recommendation that 
these techniques should be applied more generally in biopharmaceutical development. 
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These strategies are not without drawbacks. Genetically-engineered deamidated variants 
of ErA cannot mimic the presence of isoAsp residues, which are a natural result of non- 
enzymatic deamidation reactions of proteins. Furthermore, the strategy of producing 
recombinant deamidated protein variants would be self-limiting in cases where there are 
many labile Asn residues in the protein, as the number of variants that would need to be 
expressed, purified and characterized may become overwhelming. 
Further outputs of the research programme include the detailed characterization of a set of 
ErA mutants, development of a novel assay to assess protein deamidation, and 
understanding means of controlling deamidation and process consistency in ErA 
manufacture. Although this research has demonstrated that certain types of degradation 
are not necessarily an issue for ErA, it must be stressed that these factors must be 
considered for each protein on a case-by-case basis. Such endeavours are necessarily 
largely empirical in nature. It is hoped that the research and strategies presented here may 
aid others in the characterization and understanding of the effects of protein degradation. 
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